The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer
Abstract
Purpose: Bone metastases occur in approximately 80% of patients with advanced prostate cancer. Pain is common in these patients. The purpose of this study was to evaluate the effect of an intravenous bisphosphonate, pamidronate disodium, on pain control in metastatic prostate cancer patients. Patients and Methods: Two multicenter, double-blind, randomized, placebo-controlled trials were conducted in patients with bone pain due to metastatic prostate cancer, with disease progression after first-line hormonal therapy. Intravenous pamidronate disodium (90 mg) or placebo was administered every 3 weeks for 27 weeks. Efficacy was measured via self-reported pain score (Brief Pain Inventory), analgesic use, the proportion of patients with a skeletal-related event (SRE; defined as pathologic fracture, radiation or surgery to bone, spinal cord compression, or hypercalcemia), and a pilot quantitative measurement of mobility. Laboratory evaluations included serum prostate-specific antigen, interleukin-6, bone alkaline phosphatase, and urinary bone resorption markers. Results: Results of the two trials were pooled. There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27. Urinary bone resorption markers were suppressed in the pamidronate group compared with placebo. Conclusion: Pamidronate disodium failed to demonstrate a significant overall treatment benefit compared with placebo in palliation of bone pain or reduction of SREs. Evaluation of more potent bisphosphonates in patients with prostate cancer is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pain assessment: global use of the Brief Pain Inventory.
Cs, C., & Km, R. (1994) · PubMed · Cited by 5,421
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
Pain and Its Treatment in Outpatients with Metastatic Cancer
Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H., Stewart, J. A., & Pandya, K. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300902 · Cited by 2,019
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Self-citationHortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Self-citationMajor, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Self-citationBisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., Reitsma, D. J., Heffernan, M., & Seaman, J. J. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z · Cited by 665
Self-citationBerenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Self-citationHortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Self-citationTheriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 604
Self-citationPreclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., Yee, G., Biermann, J. S., Chlebowski, R. T., Pfister, D. G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1378 · Cited by 383
Carlin, B. I., & Andriole, G. L. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.0.co;2-q · Cited by 363
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body, J. J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., Kanis, J. A., Kyle, R. A., Mundy, G. R., Paterson, A. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3890 · Cited by 359
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
Garnero, P., Buchs, N., Zekri, J., Rizzoli, R., Coleman, R. E., & Delmas, P. D. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1012 · Cited by 238
Nussbaum, S. R., Younger, J., Vandepol, C. J., Gagel, R. F., Zubler, M. A., Chapman, R., Henderson, I. C., & Mallette, L. E. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90282-t · Cited by 228
In Vivo Stimulation of Endosteal Bone Formation by Basic Fibroblast Growth Factor in Rats
Mayahara, H., Ito, T., Nagai, H., Miyajima, H., Tsukuda, R., Taketomi, S., Mizoguchi, J., & Kato, K. (1993) · Growth Factors · doi:10.3109/08977199308991583 · Cited by 220
Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer
CLARKE, N. W., McCLURE, J., & GEORGE, N. J. R. (1991) · British Journal of Urology · doi:10.1111/j.1464-410x.1991.tb15260.x · Cited by 192
Lipton, A., Small, E., Saad, F., Gleason, D., Gordon, D., Smith, M., Rosen, L., Ortu Kowalski, M., Reitsma, D., & Seaman, J. (2002) · Cancer Investigation · doi:10.1081/cnv-120014886 · Cited by 175
Self-citationComparative study of available medical therapy for hypercalcemia of malignancy
Mundy, G. R., Wilkinson, R., & Heath, D. A. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90961-0 · Cited by 163
Complete amino acid sequence of human transforming growth factor type beta 2.
Marquardt, H., Lioubin, M. N., & Ikeda, T. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45325-2 · Cited by 136
Dunstan, C. R., Boyce, R. W., Boyce, B. F., Garrett, I. R., Izbicka, E., Burgess, W. H., & Mundy, G. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.6.953 · Cited by 124
Percival, R. C., Urwin, G. H., Harris, S., Yates, A. J. P., Williams, J. L., Beneton, M. N. C., & Kanis, J. A. (1987) · PubMed · Cited by 124
Dichloromethylene-Diphosphonate in Patients with Prostatic Carcinoma Metastatic to the Skeleton
Адами, С., Salvagno, G. L., Guarrera, G. M., Bianchi, G. P., Dorizzi, R. M., Rosini, S., Mobilio, G., & Cascio, V. L. (1985) · The Journal of Urology · doi:10.1016/s0022-5347(17)47663-4 · Cited by 115
Analgesic Drug Therapy in Cancer Pain: Principles and Practice
Foley, K. M., & Inturrisi, C. E. (1987) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30866-5 · Cited by 103
METABOLIC BONE DISEASE INDUCED BY PROSTATE CANCER: RATIONALE FOR THE USE OF BISPHOSPHONATES
Berruti, A., Dogliotti, L., Tucci, M., Tarabuzzi, R., Fontana, D., & Angeli, A. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65498-5 · Cited by 100
Bisphosphonates in prostate carcinoma
Adami, S. (1997) · Cancer · Cited by 89
CLARKE, N. W., McCLURE, J., & GEORGE, N. J. R. (1992) · British Journal of Urology · doi:10.1111/j.1464-410x.1992.tb15461.x · Cited by 78
Pelger, R. C. M., Hamdy, N. A. T., Zwinderman, A. H., Nijeholt, A. A. B. L. À., & Papapoulos, S. E. (1998) · Bone · doi:10.1016/s8756-3282(97)00289-5 · Cited by 75
Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study.
Clarke, N., Holbrook, I., McClure, J., & George, N. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.97 · Cited by 68
CRESSWELL, S. M., English, P., Hall, R. R., ROBERT, J. T., & Marsh, M. M. (1995) · British Journal of Urology · doi:10.1111/j.1464-410x.1995.tb07715.x · Cited by 61
Lipton, A., Glover, D. J., Harvey, H. A., Grabelsky, S. A., Zelenakas, K., Macerata, R. S., & Seaman, J. A. (1994) · PubMed · Cited by 57
Self-citationProstate cancer: a comprehensive review
Pentyala, S., Lee, J., Hsieh, K., Waltzer, W. C., Trocchia, A. M., Musacchia, L., Rebecchi, M. J., & Khan, S. (2000) · Medical Oncology · doi:10.1007/bf02796203 · Cited by 43
Opioid Responsiveness-Primary Diagnosis Relationship in Advanced Cancer Patients Followed At Home
Mercadante, S., Casuccio, A., Pumo, S., & Fulfaro, F. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00145-7 · Cited by 23
Analgesic use in home hospice cancer patients.
McCormack, A., Hunter‐Smith, D. J., Piotrowski, Z. H., GRANT, M. M., Kubik, S., & Kessel, K. (1992) · PubMed · Cited by 15
Cited by
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Self-citationSaad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C., Bangma, C., & Kataja, V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq174 · Cited by 600
Brown, J. E., Cook, R. J., Major, P., Lipton, A., Saad, F., Smith, M., Lee, K.-A., Zheng, M., Hei, Y.-J., & Coleman, R. E. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji002 · Cited by 559
Self-citationAapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Metadata
- Authors
- Small, E. J., Smith, M. R., Seaman, J. J., Petrone, S., & Kowalski, M. O.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-12-01
- Volume
- 21
- Issue
- 23
- Pages
- 4277-4284
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2027735110
- Cited by
- 341
- References
- 38
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.